Chronic myeloid leukaemia as a model of disease evolution in human cancer

被引：454

作者：

Melo, Junia V. ^{[1
]}

Barnes, David J. ^{[1
]}

机构：

[1] Hammersmith Hosp, Imperial Coll London, Dept Haematol, London W12 0NN, England

来源：

NATURE REVIEWS CANCER | 2007年 / 7卷 / 06期

关键词：

D O I：

10.1038/nrc2147

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chronic myeloid leukaemia (CML) can be considered as a paradigm for neoplasias that evolve through a multi-step process. CML is also one of the best examples of a disease that can be targeted by molecular therapy; however, the success of new 'designer drugs' is largely restricted to the chronic phase of the disease. If not cured at this stage, CML invariably progresses and transforms into an acute-type leukaemia undergoing a 'blast crisis'. The causes of this transformation are still poorly understood. What mechanisms underlie this progression, and are they shared by other common cancers?

引用

页码：441 / 453

页数：13

共 152 条

[61]

GUO JQ, 1991, CANCER RES, V51, P3048

[62] TELOMERE REDUCTION IN HUMAN COLORECTAL-CARCINOMA AND WITH AGING [J].

HASTIE, ND ;

DEMPSTER, M ;

DUNLOP, MG ;

THOMPSON, AM ;

GREEN, DK ;

ALLSHIRE, RC .

NATURE, 1990, 346 (6287) :866-868

[63] Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis:: A sequential study in 42 patients [J].

Hernández-Boluda, JC ;

Cervantes, F ;

Colomer, D ;

Vela, MC ;

Costa, D ;

Paz, MF ;

Esteller, M ;

Montserrat, E .

EXPERIMENTAL HEMATOLOGY, 2003, 31 (03) :204-210

[64] Genome maintenance mechanisms for preventing cancer [J].

Hoeijmakers, JHJ .

NATURE, 2001, 411 (6835) :366-374

[65] Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation [J].

Holtz, MS ;

Slovak, ML ;

Zhang, FY ;

Sawyers, CL ;

Forman, SJ ;

Bhatia, R .

BLOOD, 2002, 99 (10) :3792-3800

[66] Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-XL [J].

Horita, M ;

Andreu, EJ ;

Benito, A ;

Arbona, C ;

Sanz, C ;

Benet, I ;

Prosper, F ;

Fernandez-Luna, JL .

JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (06) :977-984

[67]

HUGHES T, 2006, MYELOPROLIFERATIVE D, P143

[68] Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia [J].

Hughes, TP ;

Kaeda, J ;

Branford, S ;

Rudzki, Z ;

Hochhaus, A ;

Hensley, ML ;

Gathmann, I ;

Bolton, AE ;

van Hoomissen, IC ;

Goldman, JM ;

Radich, JP ;

Taylor, K ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Lechner, K ;

Verhoef, G ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shepherd, J ;

Shustik, C ;

Lipton, J ;

Kovacs, DM ;

Turner, AR ;

Nielsen, JL ;

Birgens, H ;

Bjerrum, OW ;

Guilhot, F ;

Reiffers, J ;

Rousselot, P ;

Facon, T ;

Harousseau, JL ;

Tulliez, M ;

Guerci, A ;

Blaise, D ;

Maloisel, F ;

Michallet, M ;

Fischer, T ;

Hossfeld, D ;

Mertelsmann, R ;

Andreesen, R ;

Nerl, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (15) :1423-1432

[69] Blasts from the past: New lessons in stem cell biology from chronic myelogenous leukemia [J].

Huntly, BJP ;

Gilliland, DG .

CANCER CELL, 2004, 6 (03) :199-201

[70] P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members [J].

Ilaria, RL ;

VanEtten, RA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (49) :31704-31710

← 2 3 4 5 6 7 8 9 10 11 →